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Abstract
Background: Achieving sustainable economic and social growth through advances in health is
crucial in Latin America within the framework of the United Nations Millennium Development
Goals.
Discussion:  Health-related Millennium Development Goals need to incorporate a
multidimensional approach addressing the specific epidemiologic profile for each region of the
globe. In this regard, addressing the cycle of destitution and suffering associated with infection with
Trypanosoma cruzi, the causal agent of Chagas disease of American trypanosomiasis, will play a key
role to enable the most impoverished populations in Latin America the opportunity to achieve their
full potential. Most cases of Chagas disease occur among forgotten populations because these
diseases persist exclusively in the poorest and the most marginalized communities in Latin America.
Summary: Addressing the cycle of destitution and suffering associated with T. cruzi infection will
contribute to improve the health of the most impoverished populations in Latin America and will
ultimately grant them with the opportunity to achieve their full economic potential.
Background
The Millennium Development Goals in Latin America
In 2000, the United Nations Millennium Summit
adopted the Millennium Development Goals (MDGs) to
address extreme poverty [1]. The purpose of these goals is
multidimensional: promotion of education and environ-
mental sustainability; alleviation of hunger; fostering gen-
der equality; and improving the health of impoverished
populations to encourage economic growth and reduce
poverty and inequality [1,2]. In Latin America, these goals
were reaffirmed in the Declaration of the Special Summit
of the Americas, which was held in Monterrey, Mexico in
2004 [2]. Almost 3 years after this event, progress in pov-
erty alleviation programs is insufficient to meet the goal of
halving the proportion of people living in extreme poverty
in the region by the year 2015 [2]. In order to achieve
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these goals, more than 9 million children need to attend
school; many millions of women and girls need to enjoy
enhanced participation in society and security. In addi-
tion, people need to drink safe water, enjoy basic sanitary
conditions, allowing for healthier lives. All of these
aspects should occur within the context of environmental
sustainability [1,2].
Indeed, there are significant challenges ahead in order to
make substantial strives with the existing living condi-
tions and available resources in Latin America. In fact,
achieving sustainable growth through advances in health
is crucial in Latin America [3,4]. In addition, the fre-
quently cited causes of poor health in the region [3], a
group of diseases now defined as NTDs are responsible for
a substantial deterioration of the health status of people
living in extreme poverty [4]. They are named neglected
because these diseases persist exclusively in the poorest
and the most marginalized communities [3]. The diseases
thrive in places with unsafe water, poor sanitation, and
limited access to basic health care [4]. Despite the enor-
mous disabilities they cause, these diseases are often less
visible and given a low priority alongside high mortality
diseases. Furthermore, the economic impact of NTDs can
be staggering and thus, a never ending cycle of destitution
ensues [4]. Therefore, it is critical to adapt the health-
related MDGs to the epidemiologic profile of the region.
In this regard, Chagas disease is a premiere example of the
significant burden of disease (see next section) and suffer-
ing imposed by highly prevalent NTDs in the Americas.
The unnecessary burden of Chagas disease
Chagas disease, also known as American trypanosomiasis,
is a zoonotic tropical disease caused by the parasite
Trypanosoma cruzi [5]. Millions of inhabitants of rural
Mexico and Central and South America have, throughout
history, been burdened by Chagas disease [5-7]. Not only
does primary infection continue to endanger the lives of
countless people in the region, but the chronic manifesta-
tions of Chagas disease also affect the livelihood of many
individuals previously infected. As a result, Chagas disease
remains the most important vector-borne neglected dis-
ease in the Americas today [2]. As the trend for global
migration increases, the scope of Chagas disease threatens
to expand exponentially, from rural to urban areas and
endemic to non-endemic regions [7,8].
Despite significant decreases in infection and mortality
that have been achieved through vector and transfusion-
related control initiatives in Central and South America
over the last decade, [5,7,8] current estimates suggest that
ten to thirteen million people are chronically infected
with  Trypanosoma cruzi and approximately 90 million
individuals remain at risk of contracting the infection
[7,9]. In countries such as Mexico, increased surveillance
combined with socioeconomic deterioration, especially
in the Southern States, has led to increased incidence of
Chagas (Figure 1) [10].
American trypanosomiasis manifests with acute and
chronic (early and late) phases [5,7-9,11]. In some indi-
viduals, parasitization of cardiac muscle or brain during
acute infection can lead to myocarditis or meningoen-
cephalitis, respectively. If left untreated, the acute phase
progresses to a subclinical latent period after several weeks
(chronic early) and eventually may progress to a chronic
late phase. Approximately 20 to 30% of those chronically
infected are symptomatic [7-9]. For example, persistent T.
cruzi infection can lead to unremitting inflammation in
the myocardium, disrupting the cardiac conduction sys-
tem and producing structural alterations. These events
result in cardiac arrhythmias, congestive heart failure,
thromboembolic events, and sudden cardiac death [5,7-
9]. Destruction of visceral autonomic neurons in the
digestive tract results in progressive dilation of the
esophagus and colon and gastrointestinal dysmotility
[5,11]. Unlike Chagas disease seen in immunocompetent
patients, meningoencephalitis dominates the clinical pic-
ture in untreated HIV-infected patients [12].
As in all neglected diseases, Chagas disease creates finan-
cial and social burdens to the individual, his or her house-
hold and country, and continental Latin America [13-15].
Estimates suggest that the burden of Chagas disease in this
region is, in fact, five to ten times larger than that of
malaria [2]. The early mortality and substantial disability
Title Incidence of Chagas disease in Mexico, 1990–2005 Figure 1
Title Incidence of Chagas disease in Mexico, 1990–
2005. * Includes acute and chronic cases Source: Ministry of 
Health, Mexico CENEVECE (1990 – 2005) per 100 000 pop-
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caused by this disease, which often occurs in the most pro-
ductive population, young adults, results in a devastating
economic loss in the Americas. In 1995, this was esti-
mated at US$8,156 million, which is equivalent to 2.5%
of the external debt of continental Latin America [14,15].
Older estimates suggest that $300 million dollars were
lost in Brazil between 1979 and 1981 based on the total
number of cases of Chagas disease in that country during
that period of time [14,15]. More recent data demonstrate
that globally, Chagas disease is associated with 14,000
deaths per year and 0.7 million disability-adjusted life-
years, constituting the sixth most important neglected
tropical disease worldwide [16].
Discussion
Poverty as the underlying determinant of Chagas disease
" If it wasn't for typhus, malaria, Chagas disease, igno-
rance, and other highly successful plagues luckily spread
out in rural areas, how would we extend the limits of
our haciendas?, Without these plagues, how would we
able to promote enough fear, and being able to continue
to exploit the poor in the most effective way?[17]"
Populations at risk of acquiring vector-borne, blood trans-
fusion related, and congenital T. cruzi infection are often
bound more by socioeconomic status than by latitude
[15]. The most impoverished populations live in poor
quality housing with substandard conditions across Latin
America that constitute a prime habitat for T. cruzi vectors
[1,10-12,16]. Unsafe blood-transfusion practices and
inadequate access to adequate prenatal care offers the
opportunity for Chagas disease to ravage underserved,
vulnerable populations [11,15].
Vector-borne cases, the most important form of acquisi-
tion of the disease, result from the pervasive presence of
transmitting vectors in poorly constructed human dwell-
ings [5,11,14,18,19]. Transmission arises when insects of
the Reduviidae family, subfamily Triatominae bite humans
or other mammals. While the triatome ingests a blood
meal, inoculation occurs as T. cruzi is excreted via feces
into breaks in the skin or mucosa of the victim (Figure 2)
[5,7,11]. Although a large number of species exist, the
most important vectors to humans are Triatoma infestans,
Rhodnius prolixus,  Triatoma dimidiata, and Panstrongylus
megistus [7,15,18,19]. The triatomes' wild habitat typically
includes palm trees, tree holes, burrows, rock crevices, or
Title Cycle of transmission of Trypanosoma cruzi and its vectors to humans Figure 2
Title Cycle of transmission of Trypanosoma cruzi and its vectors to humans. Triatomine bugs live in the crevices of 
poorly constructed houses in impoverished areas in Latin America. Metacyclic trypomastigote is the infecting form to humans, 
while the amastigote is the intracellular form responsible for the immunopathogenesis in target human organs.
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other animal refuges, but some of these insects have
learned to adapt to live and thrive in human dwellings.
During the day, triatomines may hide in dark crevices or
in unplastered, cracked walls of mud or mud-brick houses
[18,19]. In order to meet their basic needs and ensure
their immediate survival, many individuals are forced to
accept the long-term consequences of sharing their house-
hold with these vectors. In many Latin American cities
where Chagas disease is endemic, unregulated urbaniza-
tion and widespread emergence of shantytowns has cre-
ated serious strain on community resources and left many
neighborhoods without a basic infrastructure, further
exacerbating the cycle of destitution associated with this
disease [3-5,11,19]. Furthermore, triatomines living in the
peridomestic and sylvatic environments can also be trans-
mitted by contaminated food with the consequent oral
transmission resulting in microepidemics of acute cases of
Chagas disease [20].
Poor housing, lack of access to safe blood-bank supplies,
and inadequate prenatal care are linked to social and
health inequalities that prevail in many areas of Latin
America [5,7,15-18,21]. Such related social ills occur
among the most impoverished Latin American popula-
tions and their roots are entrenched within large-scale
social structures – political and economical [4]. Many
people forgotten by their governments are coincidentally,
the same people who encounter infection with T. cruzi.
The vast majority with Chagas has the lowest incomes,
poor sanitation and nutrition, the worst opportunities for
education, low quality housing, and endure an inter-gen-
erational persistence of social inequalities [3,4]. Poverty
not only restricts patients' access to diagnosis and treat-
ment of the disease [4,11,16], but it leads to malnutrition,
thereby limiting an individual's ability to recover and
return to work. In a vicious cycle, poor living conditions
lead to increased incidence of Chagas disease which crip-
ples the population leaving it unable to work, gain reve-
nue, and reach its full potential [4]. Poverty and
underdevelopment, therefore, persist.
Many of the ill have also been exploited and deprived of
basic human rights by either members of the wealthy
social classes or their governments [4]. Some marginal-
ized groups, feeling that there is no alternative to their sur-
vival, manifest their misery and hunger for social equity
with uprisings against the inequalities that have reigned
their lives for decades [4,17]. An illustration of these
upheavals occurred in response to the growing health and
social inequalities prevailing in Chiapas Mexico in 1994.
Pleading for justice, subcomandante Marcos wrote a letter
to the Mexican government which declared: "Should we ask
pardon from the dead, those who die of 'natural' deaths of 'nat-
ural causes' like measles, whooping cough, Chagas disease,
cholera, typhoid, tetanus, pneumonia, gastrointestinal infec-
tions, and malaria?..... Our dead, the democratically dead,
dying from sorrow because no one did anything, because the
dead, our dead, went just like that, without anyone saying
enough."
Chagas disease and the Millennium Development Goals
Chagas disease and other neglected diseases separate
those living in endemic areas from the moral premise of
the Universal Declaration of Human Rights and far from
contributing to the achievement the MDGs [1,2,4].
Untreated Chagas disease impairs human development in
this region by producing substantial morbidity, prema-
ture death, and disability that limits the ability of both
current and future generations to meet their basic human
requirements including sufficient income [1,2,4]. Addi-
tionally, the direct and indirect costs of T. cruzi infection
impose an overwhelming load to the healthcare system
secondary to hospitalizations and medical and surgical
treatments for chagasic cardiomyopathy, gastrointestinal
dysfunction, and meningoencephalitis [14,15]. Of course,
this only applies to those individuals that can afford or
who have access to healthcare.
In order to reach the MDGs in Latin America by 2015,
approximately 118 million people will have to be lifted
out of extreme poverty [2]. Public health policies and pro-
grams directed at controlling neglected tropical diseases in
Latin America, in particular, Chagas disease must occur
concomitantly with policies to accelerate investment,
reduce poverty, and promote social development [1,4]. In
this regard, control of Chagas disease requires that each
mode of transmission be addressed. The main challenges
in the new millennium, therefore, include vector control
programs, housing improvement programs, comprehen-
sive and easily accessible medical care, continuation and
expansion of blood-screening programs, and treatment of
currently infected individuals.
Vector control programs
There have been successes in the battle against Chagas dis-
ease using household insecticides and blood-bank screen-
ing through the Southern Cone Initiative [14,15,18-20]
Continued vector control activities with consolidation of
operational control programs and continued political
commitment with strong leadership and synchronization
of efforts among the programs managed through the dif-
ferent Latin American governments is required for sustain-
able success [3,4]. Impregnated mosquito nets may also
be useful for self-protection, particularly in areas with geo-
graphic overlap with malaria [16]. Despite some improve-
ments in the control of this infection and the importance
of vector control programs, T. cruzi infects several insect
species and has multiple animal reservoirs. Successful
elimination of one species, as it has occurred in domestic
Chagas disease transmission in Brazil and other SouthernBMC International Health and Human Rights 2007, 7:7 http://www.biomedcentral.com/1472-698X/7/7
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Cone Initiative countries, may lead to the occupation of
vacant niches by other triatomines species. As an example
some the golden lion tamarins in the Poço das Antas
National Park (only 60 km from Rio de Janeiro) have
been recently found to be infected with the type II lineage
of T. cruzi. In this manner, sylvatic species may adapt to an
anthropomotic transmission, and reinvasion of insects
from sylvatic transmission cycles becomes a major chal-
lenge for Chagas disease control [19,20].
Growing efforts to prevent further transmission through
blood transfusion and organ donation screening pro-
grams are also fundamental [9-11,18,21].
Housing improvement programs
Combining vector control practices with housing
improvement initiatives will concomitantly target many
MDGs [12,15,20]. By modifying houses and their imme-
diate surroundings, long-term protection from triatomine
bugs can be achieved. Filling cracks in walls and roofs
with plaster prepared from locally available materials can
decrease the number of resting places for the insects in a
cost-effective manner [10,11]. Additionally, coating
house-frames, walls and roofs with insecticidal paints in
endemic areas has shown some benefit [3,10,11]. The
addition of educational campaigns to modify storage
places for agricultural products, firewood or other belong-
ings to current campaigns such as those existing for den-
gue fever, may promote the reduction of habitats for the
vectors [7]. Fortunately, these improvements are relatively
economical when compared with the cost of chronic Cha-
gas disease. It has been estimated that the cost to improve
or construct more than 700,000 dwellings in rural Brazil
is equal to US$750 million, the same amount spent annu-
ally in Brazil for medical and surgical management of
chronic Chagas disease [14,15].
Improved case management
Control of Chagas disease requires adequate treatment of
chronic cases of the disease. Currently, there is no ade-
quate treatment for chronic late cases, which are associ-
ated with most of the morbidity and mortality of Chagas
disease [5,8,11]. Nifurtimox and benznidazole are effec-
tive only in the treatment of acute and chronic early phase
cases and work primarily by preventing the occurrence of
late chronic disease [8,11]. Expanding knowledge of para-
site metabolism has renewed hope for effective chemo-
therapy for chronic phase T. cruzi infection [8,11]. Drug
targets consist of recently identified critical metabolic
pathways in the life cycle of this parasite, including block-
age of sterol synthesis, cysteine protease metabolism, far-
nesyl pyrophosphate and others. Parasitologic
elimination using the above strategies may provide an
opportunity to prevent the onset of late manifestations
when used early and even halt the progression of the dis-
ease when used late [8,11]. In addition, efforts to control
Chagas disease, modeled after the rapid-impact programs
to alleviate the burden of tropical neglected diseases in
sub-Saharan Africa [16], could have a rapid and visible
payoff on the health status of millions in Latin America.
Summary
We should take advantage of the growing momentum in
the fight against neglected tropical diseases. In this regard,
a new effort to eliminate Chagas disease by 2010 has been
recently launched by WHO through the establishment of
a Global network to combat the disease. This collabora-
tive initiative involves WHO Headquarters, the PAHO,
non-governmental organizations, academic centers, and
pharmaceutical industry [22]. Addressing the cycle of des-
titution and suffering associated with T. cruzi infection
will ultimately grant the most impoverished populations
in Latin America the opportunity to achieve their full
potential. American trypanosomiasis can cease to be the
shameful shadow that defines poverty and underdevelop-
ment in Latin America [5].
Abbreviations
MDGs, Millennium Development Goals; NTDs,
Neglected Tropical Diseases; WHO, World Health Organ-
ization; PAHO, Pan-American Health Organization
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CFP conceived the idea of this work and contributed to
the writing of the manuscript. AV conceived the idea of
this work and contributed to the writing of the manu-
script. AJRM conceived the idea of this work and contrib-
uted to the writing of the manuscript. IT conceived the
idea of this work and contributed to the writing of the
manuscript. AH conceived the idea of this work and con-
tributed to the writing of the manuscript. DJ participated
in the review of the literature and to the writing of the
manuscript and also in the revised version of the manu-
script. MB participated in the review of the literature and
to the writing of the manuscript and also in the revised
version of the manuscript. CGN participated in the writ-
ing of the manuscript and senior experts in the topic of
vector-borne diseases in Latin America. JM participated in
the writing of the manuscript and senior experts in the
topic of vector-borne diseases in Latin America All authors
read and approved the final manuscript.
Acknowledgements
None.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC International Health and Human Rights 2007, 7:7 http://www.biomedcentral.com/1472-698X/7/7
Page 6 of 6
(page number not for citation purposes)
References
1. Sachs JD, McArthur JW: The Millennium Project: a plan for
meeting the Millennium Development Goals.  Lancet 2005,
365(9456):347-53.
2. Inter-American Development Bank: The Millennium Develop-
ment Goals in Latin America and the Caribbean: Progress,
priorities and IDB support for their implementation.  Inter-
American Development Bank, Washington D.C; 2005:1-70. 
3. Riley LW, Ko AI, Unger A, Reis MG: Slum health: diseases of
neglected populations.  BMC International Health and Human Rights
2007, 7:2. doi:10.1186/1472-698X-7-2.
4. Franco-Paredes C, Jones D, Rodriguez-Morales AJ, Santos-Preciado JI:
Improving the health of neglected populations in Latin
America.  BMC Public Health 2007, 7:11. doi: 10.1186/1471-2458-7-
11
5. Pinto Dias JC: The treatment of Chagas disease (South Amer-
ican trypanosomiasis).  Ann Intern Med 2006, 144(10):772-774.
6. Aufderheide AC, Salo W, Madden M, Streitz J, Buikstra J, Guhl F, Arri-
aza B, Renier C, Wittmers LE, Fornaciari G, Allison M: A 9,000-year
record of Chagas disease.  Proc Natl Acad Sci 2004,
101(7):2034-2039.
7. World Health Organization: Chagas disease information.  The
UNICEF-UNDP- Programme on TDR  [http://www.who.int/tdr/diseases/
chagas/].
8. The Lancet: Chagas disease – an epidemic that can no longer
be ignored.  Lancet 2006, 368:619.
9. Maguire JH: Chagas disease-Can we stop the deaths?  N Engl J
Med 2006, 355(8):760-761.
10. Attaran A: Chagas' disease in Mexico.  Lancet 2006,
368(9459):1768-69.
11. Urbina JA, Docampo R: Specific chemotherapy of Chagas dis-
ease: controversies and advances.  Trends Parasitol 2003,
19(11):495-501.
12. CDC/NIH/ATS: Treating opportunistic infections among HIV-
infected adults and adolescents.  MMWR 2005, 53(RR-
15):63-65.
13. Schofeld CJ, Dias JC: The southern cone initiative against Cha-
gas disease.  Adv Parasitol 1999, 42:1-27.
14. Moncayo A: Progress towards the elimination of transmission
of Chagas disease in Latin America.  World Health Stat Q 1997,
50(3–4):195-8.
15. Moncayo A: Chagas Disease: Current epidemiological trends
after the interruption of vectorial and transfusional trans-
mission in the southern cone countries.  Volume 98. Issue 5 Mem
Inst Owaldo Cruz, Rio de Janeiro; 2003:577-591. 
16. Hotez P, Molyneux DH, Fenwick A, Ottessen E, Ehrlich Sachs S, Sachs
JD: Incorporating a rapid-impact package for neglected trop-
ical diseases with programs for HIV/AIDS, tuberculosis, and
malaria.  PLoS Med 2006, 3(5):e102.
17. Amado Jorge: Tereza Batista cansada de guerra.  Ed Record. Río
de Janeiro; 1987. 
18. Miles MA, Feliciangeli MD, Rojas de Arias A: American trypano-
somiasis (Chagas disease) and the role of molecular epidemi-
ology in guiding control strategies.  Brit Med J 2003,
326:1444-1448.
19. Cecere MC, Vazquez-Prokopec GM, Gurtler RE, Kitron U: Spatio-
tempral analysis of reinfestation by Triatoma infestans
(Hemiptera: Reduviidae) following insecticide spraying in a
rural community in Northwestern Argentina.  Am J Trop Med
Hyg 2004, 7(6):803-810.
20. De Souza W: Chagas' disease: facts and reality.  Microbes Infect
2007:544-545.
21. Schmunis GA, Cruz JR: Safety of blood supply in Latin America.
Clin Microb Rev 2005, 18(1):12-29.
22. World Health Organization: New global effort to eliminate Cha-
gas disease.   [http://www.who.int/mediacentre/news/releases/
2007/pr36/en/index.html].
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-698X/7/7/prepub